44 / 53
Characteristic
EXP1
(n=30)
EXP2 +
EXP3A
(n=59)
EXP3B
(n=27)
EXP4 + EXP5
(n=111)
EXP6
(n=47)
Prior therapy for
NSCLC
Treatment-
naive
EXP2, crizotinib
only
EXP3A, crizotinib
+ CT
Non-crizotinib TKI
± CT
EXP4, 2 ALK TKIs
± CT
EXP5, 3 ALK TKIs
± CT
Any
Age, years
Mean (SD)
Range
57.4 (12.1)
27–75
54.9 (12.5)
30–85
55.1 (11.9)
33–77
51.9 (11.5)
29–83
52.8 (12.9)
19–77
Sex, n (%)
Female
Male
13 (43)
17 (57)
39 (66)
20 (34)
16 (59)
11 (41)
62 (56)
49 (44)
27 (57)
20 (43)
Race, n (%)
White
Black
Asian
Other
Unspecified
10 (33)
1 (3)
17 (57)
1 (3)
1 (3)
31 (53)
0 (0)
17 (29)
2 (3)
9 (15)
7 (26)
1 (4)
16 (59)
0 (0)
3 (11)
59 (53)
0 (0)
37 (33)
5 (5)
10 (9)
25 (53)
1 (2)
16 (34)
3 (6)
2 (4)
Brain
metastases, n (%)
Present
8 (27)
37 (63)
12 (44)
83 (75)
25 (53)
Demographics and Baseline Characteristics